A 42-year-old woman with cystic fibrosis is hospitalized for acute exacerbation of Pseudomonas aeruginosa lung infection. She is started on tobramycin 5 mg/kg IV once daily (extended-interval dosing). On day 3, her serum tobramycin trough level is 1.8 µg/mL (target trough <1 µg/mL for once-daily dosing). She remains febrile with persistent respiratory symptoms. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient with cystic fibrosis (CF) has a **supratherapeutic tobramycin trough level** of 1.8 µg/mL on extended-interval dosing (EID). The target trough for once-daily aminoglycoside dosing is **<1 µg/mL**. An elevated trough indicates **drug accumulation**, which signals: - Reduced renal clearance relative to the dose administered - Increased risk of nephrotoxicity and ototoxicity if dosing continues unchanged - The need for **interval extension** (not dose escalation) to allow adequate drug washout **Key Point:** In extended-interval dosing (EID), the trough level is the primary safety parameter. A trough **above target** does NOT mean underdosing — it means the drug is accumulating and the dosing interval needs to be extended, OR the dose needs to be reduced. The appropriate response is to **extend the dosing interval or reduce the dose**, then recheck levels — not to escalate the dose. ## Why Continuing Current Dose with Reassessment Is the Most Appropriate Next Step **High-Yield:** For extended-interval dosing (EID) of aminoglycosides: - **Peak level target:** 15–30 µg/mL (drives bactericidal activity via concentration-dependent killing) - **Trough level target:** <1 µg/mL (minimizes nephrotoxicity and ototoxicity) - **Elevated trough (>1 µg/mL):** Indicates accumulation → extend interval or reduce dose; do NOT increase dose In this clinical scenario, the peak level is not provided. The trough of 1.8 µg/mL indicates accumulation, not underdosing. Increasing the dose (Option A) would worsen accumulation and increase toxicity risk without improving efficacy. The safest and most appropriate immediate step is to **continue current therapy with close monitoring**, reassess clinical response at day 5–7, and obtain repeat levels — allowing time to adjust the interval based on pharmacokinetic data. **Clinical Pearl (per Sanford Guide and CF Foundation guidelines):** In CF patients, aminoglycoside pharmacokinetics are variable. While CF patients often have increased Vd and renal clearance requiring higher doses, an **elevated trough on day 3** indicates this particular patient is NOT clearing the drug rapidly. Dose escalation in the setting of a supratherapeutic trough is contraindicated and risks serious toxicity. ## Pharmacokinetic Interpretation of EID Trough Levels | Trough Level | Interpretation | Action | |---|---|---| | <1 µg/mL | Adequate clearance, low toxicity risk | Continue current dose | | 1–2 µg/mL | Accumulation; toxicity risk rising | Extend interval or reduce dose; recheck levels | | >2 µg/mL | High toxicity risk | Hold dose; extend interval significantly | This patient's trough of **1.8 µg/mL** falls in the accumulation range. The correct response is interval extension or dose reduction with reassessment — not dose escalation. ## Why Other Options Are Wrong | Option | Rationale | |--------|-----------| | **A) Increase dose to 7 mg/kg** | **Incorrect.** Increasing the dose when the trough is already supratherapeutic will worsen drug accumulation and increase nephrotoxicity/ototoxicity risk. Dose escalation is only appropriate when trough is <1 µg/mL and peak is subtherapeutic. | | **B) Switch to conventional BID/TID dosing** | Incorrect. Conventional dosing produces higher troughs and lower peaks, which increases toxicity and reduces the concentration-dependent killing advantage of EID. This is a step backward in management. | | **C) Discontinue tobramycin, switch to ciprofloxacin** | Premature. The drug has not been pharmacokinetically optimized. Switching antibiotics before optimizing dosing is not appropriate at day 3. | **Warning:** Do NOT confuse an elevated trough with underdosing. In EID, an elevated trough means the drug is **accumulating** (insufficient clearance between doses), not that the dose is too low. Increasing the dose in this setting is a dangerous error. ## Summary **The correct next step is to continue tobramycin at the current dose, reassess clinical response at day 5–7, and obtain repeat levels** because: 1. The trough of 1.8 µg/mL indicates drug accumulation, not underdosing 2. Increasing the dose would worsen accumulation and increase toxicity risk 3. Clinical response at day 3 is still early; reassessment at day 5–7 is appropriate 4. Repeat levels will guide interval adjustment (extending the interval is the pharmacokinetically correct response to a supratherapeutic trough) 5. Switching antibiotics or dosing regimens is premature before optimizing current therapy *(References: Sanford Guide to Antimicrobial Therapy; KD Tripathi Essentials of Medical Pharmacology, 8th ed.; Cystic Fibrosis Foundation Pulmonary Guidelines)*